ArticleImmunity2016
Ikaros Inhibits Group 3 Innate Lymphoid Cell Development and Function by Suppressing the Aryl Hydrocarbon Receptor Pathway.
Article in Immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Dysregulated immunometabolism in gut inflammation.Acta biochimica et biophysica Sinica · 2026Review
- Article
- Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases.Frontiers in immunology · 2024Review
- Article
- Nutrition impact on ILC3 maintenance and function centers on a cell-intrinsic CD71-iron axis.Nature immunology · 2023Article
- Gut microbe-derived milnacipran enhances tolerance to gut ischemia/reperfusion injury.Cell reports. Medicine · 2023Article
- Innate lymphoid cells: a new key player in atopic dermatitis.Frontiers in immunology · 2023Review
- Transcriptional control of ILC identity.Frontiers in immunology · 2023Review
- ILC3: a case of conflicted identity.Frontiers in immunology · 2023Review
- Transcriptional regulation of innate lymphoid cells and T cells by aryl hydrocarbon receptor.Frontiers in immunology · 2023Review
- Review
- Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity.Trends in immunology · 2022Review
- The transcription factor HIF-1α mediates plasticity of NKp46+ innate lymphoid cells in the gut.The Journal of experimental medicine · 2022Article
- LRBA Deficiency Can Lead to Lethal Colitis That Is Diminished by SHIP1 Agonism.Frontiers in immunology · 2022Article
- Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function.Blood advances · 2021Article
- Established and emergent roles for Ikaros transcription factors in lymphoid cell development and function.Immunological reviews · 2021Review
- Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease.Clinical & translational immunology · 2021Article
- Ikaros Proteins in Tumor: Current Perspectives and New Developments.Frontiers in molecular biosciences · 2021Review
- Activation and Suppression of Group 3 Innate Lymphoid Cells in the Gut.Trends in immunology · 2020Review
- The role of innate lymphoid cells in response to microbes at mucosal surfaces.Mucosal immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Group 3 innate lymphoid cells (ILC3s) expressing the transcription factor (TF) RORγt are important for the defense and homeostasis of host intestinal tissues. The zinc finger TF Ikaros, encoded by Ikzf1, is essential for the development of RORγt(+) fetal lymphoid tissue inducer (LTi) cells and lymphoid organogenesis, but its role in postnatal ILC3s is unknown. Here, we show that small-intestinal ILC3s had lower Ikaros expression than ILC precursors and other ILC subsets. Ikaros inhibited ILC3s in a cell-intrinsic manner through zinc-finger-dependent inhibition of transcriptional activity of the aryl hydrocarbon receptor, a key regulator of ILC3 maintenance and function. Ablation of Ikzf1 in RORγt(+) ILC3s resulted in increased expansion and cytokine production of intestinal ILC3s and protection against infection and colitis. Therefore, in contrast to being required for LTi development, Ikaros inhibits postnatal ILC3 development and function to regulate gut immune responses at steady state and in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.